论文部分内容阅读
目的:总结国内外基于蛋白质组学技术的肾癌标志研究进展。方法:检索PubMed和HighWire press期刊全文数据库检索系统,以“肾癌和生物标志、蛋白质组学和肾癌”为关键词,检索2003-2011年蛋白质组学技术与肾癌标志研究的相关文献。纳入标准:1)蛋白质组学研究技术;2)应用蛋白质组学技术筛选及鉴定肾癌标志;3)肾癌标志研究的进展。根据纳入标准符合分析的文献38篇。结果:蛋白质组学技术的飞速发展为肾癌标志研究提供了新的技术平台,应用蛋白质组学技术已发现了一批与肾癌发生发展可能相关的潜在生物标志,如Vimentin、CAIX、AnnexinⅡ和SAA等,在肾癌的早期诊断、治疗和预后判断方面显示出一定价值。结论:蛋白质组学技术在肾癌标志的鉴定方面具有显著的优势,基于蛋白质组学技术的肾癌标志研究推动了肾癌早期诊断、治疗和预后判断的发展。
OBJECTIVE: To summarize the research progress of kidney cancer markers based on proteomics both at home and abroad. METHODS: The PubMed and HighWire press full-text database search systems were searched. The key words of “Renal cancer and biomarkers, proteomics and kidney cancer” were retrieved. The correlation between proteomics and renal cell carcinoma markers was searched from 2003 to 2011 literature. Inclusion criteria: 1) Proteomics research technology; 2) Screening and identification of renal cancer markers using proteomic techniques; and 3) Progress in renal cancer marker research. According to the inclusion criteria, 38 articles were analyzed. Results: The rapid development of proteomics technology provided a new technology platform for the study of renal cell carcinoma markers. A number of potential biomarkers related to the development of renal cell carcinoma have been found using proteomics techniques such as Vimentin, CAIX, Annexin Ⅱ and SAA, etc., in the early diagnosis, treatment and prognosis of renal cell carcinoma showed some value. Conclusion: Proteomics has significant advantages in the identification of renal cell carcinoma markers. The study of renal cell carcinoma based on proteomics has promoted the development of early diagnosis, treatment and prognosis of renal cell carcinoma.